GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

Paris, France, October 25, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Barrett Katz, M.D., M.B.A., as Chief Medical Officer, effective November 1, 2017. Dr. Katz replaces Mohamed Genead, M.D., who resigned from the position for personal reasons.

Please find the full PDF press release attached.

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: Gensight Biologics